Immunogénétique : Libre accès

Immunogénétique : Libre accès
Libre accès


Cost-Effectiveness Analysis of Ultra Hypo-Fractionated Radiotherapy and Conventionally Fractionated Radiotherapy for Intermediate to High Risk Localized Prostate Cancer

Jiaoxue He, Qingfeng Wang, Qiancheng Hu, Changlin Li*

Background: Radiotherapy is an effective curative treatment option for intermediate-to-high-risk localized prostate cancer. Given that no significant difference was observed in survival and toxicities, we evaluated the cost-effectiveness of ultra-hypo fractionated radiotherapy and conventionally fractionated radiotherapy for intermediate-to-high-risk localized prostate cancer from the Chinese payer perspective.

Methods: We developed a Markov model with a 15-year time horizon to compare the cost and effectiveness of ultra- hypo fractionated radiotherapy with those of conventionally fractionated radiotherapy for localized intermediate- to-high-risk prostate cancer. Outcomes were measured in Quality-Adjusted Life-Years (QALYs), Incremental Cost- Effectiveness Ratio (ICER), and Willingness-To-Pay (WTP). Univariable and probability sensitivity analyses were performed to evaluate the robustness of the Markov model.

Results: Based on the results of our Markov model, the conventionally fractionated radiotherapy yielded 2.32 QALYs compared with 2.14 QALYs in the ultra-hypo fractionated radiotherapy in China. The cost of ultra-hypo fractionated radiotherapy was found to be decreased by about 14% folds ($4251.04) in comparison to that of conventionally fractionated radiotherapy. The ICER of conventionally fractionated radiotherapy vs the ultra-hypo fractionated radiotherapy was $23,616.89 per QALY in China. The most sensitive parameters were the ultra-hypo fractionated radiotherapy utility of Failure-Free Survival (FFS) with grade two or worse urinary toxicity and discount rate per annum. The cost effectiveness acceptability curve showed that conventionally fractionated radiotherapy had a 57.7% probability of being cost-effective at the Chinese WTP threshold.

Conclusion: The ultra-hypo fractionated radiotherapy was not a cost-effective strategy compared with conventionally fractionated radiotherapy in patients with localized intermediate-to-high-risk prostate cancer from the perspective of the Chinese payers. However, steep reductions in the grade two or worse urinary toxicity of the ultra-hypo fractionated radiotherapy could alter the results.